Open Orphan #ORPH – New Contract win for Open Orphan’s Breda office

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a new contract win of c. €900,000 with an existing customer for clinical trial management by our Breda, Netherlands office. Cathal Friel, Executive Chairman of Open […]

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its […]

Open Orphan #ORPH – Option to Acquire CHIMagents Limited

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce it has signed an option to acquire (the “Option”) CHIMagents Limited (“CHIMagents”) for a nominal sum. CHIMagents was recently established to assist […]